135 related articles for article (PubMed ID: 36746036)
1. A review on the role of ADAMTS9-AS2 in different disorders.
Ghafouri-Fard S; Askari A; Hussen BM; Baniahmad A; Taheri M; Mokhtari M
Pathol Res Pract; 2023 Mar; 243():154346. PubMed ID: 36746036
[TBL] [Abstract][Full Text] [Related]
2. LncRNA ADAMTS9-AS2 inhibits cell proliferation and decreases chemoresistance in clear cell renal cell carcinoma via the miR-27a-3p/FOXO1 axis.
Song EL; Xing L; Wang L; Song WT; Li DB; Wang Y; Gu YW; Liu MM; Ni WJ; Zhang P; Ma X; Zhang X; Yao J; Chen Y; An RH
Aging (Albany NY); 2019 Aug; 11(15):5705-5725. PubMed ID: 31400752
[TBL] [Abstract][Full Text] [Related]
3. ADAMTS9-AS2 regulates PPP1R12B by adsorbing miR-196b-5p and affects cell cycle-related signaling pathways inhibiting the malignant process of esophageal cancer.
Chen Z; Tang W; Ye W; Song L; Chen Z
Cell Cycle; 2022 Aug; 21(16):1710-1725. PubMed ID: 35503407
[TBL] [Abstract][Full Text] [Related]
4. ADAMTS9-AS2 Promotes Angiogenesis of Brain Microvascular Endothelial Cells Through Regulating miR-185-5p/IGFBP-2 Axis in Ischemic Stroke.
Feng N; Wang Z; Wu Y; Zheng H; Jiang X; Wang Z; Qu F; Zhang Z
Mol Neurobiol; 2022 Apr; 59(4):2593-2604. PubMed ID: 35098480
[TBL] [Abstract][Full Text] [Related]
5. LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis.
Li Y; Wan Q; Wang W; Mai L; Sha L; Mashrah M; Lin Z; Pan C
Biomed Pharmacother; 2019 Apr; 112():108719. PubMed ID: 30970517
[TBL] [Abstract][Full Text] [Related]
6. LncRNA ADAMTS9-AS2 regulates ovarian cancer progression by targeting miR-182-5p/FOXF2 signaling pathway.
Wang A; Jin C; Li H; Qin Q; Li L
Int J Biol Macromol; 2018 Dec; 120(Pt B):1705-1713. PubMed ID: 30268751
[TBL] [Abstract][Full Text] [Related]
7. LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis.
Ren N; Jiang T; Wang C; Xie S; Xing Y; Piao D; Zhang T; Zhu Y
Aging (Albany NY); 2020 Jun; 12(11):11025-11041. PubMed ID: 32516127
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of lncRNA ADAMTS9-AS2 Promotes Salivary Adenoid Cystic Carcinoma Metastasis via PI3K/Akt and MEK/Erk Signaling.
Xie S; Yu X; Li Y; Ma H; Fan S; Chen W; Pan G; Wang W; Zhang H; Li J; Lin Z
Mol Ther; 2018 Dec; 26(12):2766-2778. PubMed ID: 30217729
[TBL] [Abstract][Full Text] [Related]
9. Long-Chain Noncoding RNA ADAMTS9-AS2 Regulates Proliferation, Migration, and Apoptosis in Bladder Cancer Cells Through Regulating miR-182-5p.
Guo Q; Ni P; Dai Y; Hu J; Yao Y
J Interferon Cytokine Res; 2021 Feb; 41(2):60-71. PubMed ID: 33621133
[TBL] [Abstract][Full Text] [Related]
10. Upregulated lncRNA ADAMTS9-AS2 suppresses progression of lung cancer through inhibition of miR-223-3p and promotion of TGFBR3.
Liu C; Yang Z; Deng Z; Zhou Y; Gong Q; Zhao R; Chen T
IUBMB Life; 2018 Jun; 70(6):536-546. PubMed ID: 29707897
[TBL] [Abstract][Full Text] [Related]
11. ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis.
Xu W; Wang B; Cai Y; Chen J; Lv X; Guo C; Yuan C
Curr Pharm Des; 2021; 27(23):2722-2727. PubMed ID: 33823762
[TBL] [Abstract][Full Text] [Related]
12. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
Shi YF; Lu H; Wang HB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
[TBL] [Abstract][Full Text] [Related]
13. M6A Promotes Colorectal Cancer Progression via Regulating the miR-27a-3p/BTG2 Pathway.
Liu W; Zhang Z; Luo X; Qian K; Huang B; Deng J; Yang C
J Oncol; 2023; 2023():7097909. PubMed ID: 36816363
[TBL] [Abstract][Full Text] [Related]
14. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
[TBL] [Abstract][Full Text] [Related]
15.
Shen FF; Zhang F; Yang HJ; Li JK; Su JF; Yu PT; Zhou FY; Che GW
Biomark Med; 2020 Oct; 14(15):1415-1426. PubMed ID: 32892630
[No Abstract] [Full Text] [Related]
16. Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1.
Wang YG; Wang T; Shi M; Zhai B
J Exp Clin Cancer Res; 2019 Apr; 38(1):153. PubMed ID: 30971290
[TBL] [Abstract][Full Text] [Related]
17. LncRNA NFIA-AS2 promotes glioma progression through modulating the miR-655-3p/ZFX axis.
Xin J; Zhao YH; Zhang XY; Tian LQ
Hum Cell; 2020 Oct; 33(4):1273-1280. PubMed ID: 32779154
[TBL] [Abstract][Full Text] [Related]
18. LncRNA ADAMTS9-AS2 regulates periodontal ligament cell migration under mechanical compression via ADAMTS9/fibronectin.
Yu Q; Guo K; Yang Y; Liu H; Huang Y; Li W
J Periodontal Res; 2024 Feb; 59(1):174-186. PubMed ID: 37957805
[TBL] [Abstract][Full Text] [Related]
19. LncRNA HOXA-AS2 promotes the progression of prostate cancer via targeting miR-509-3p/PBX3 axis.
Xiao S; Song B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32519740
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop.
Zhang X; Niu W; Mu M; Hu S; Niu C
J Exp Clin Cancer Res; 2020 Sep; 39(1):196. PubMed ID: 32962742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
